Cancer-associated fibroblasts, key drivers of tumorigenesis by Pidelaserra Martí, Gemma & Universitat Autònoma de Barcelona. Facultat de Biociències
Cancer-associated fibroblasts, key drivers of tumorigenesis
Gemma Pidelaserra Martí, Bachelor in Biotechnology, Faculty of Biosciences, UAB, 2015
 To describe cancer-associated fibroblasts (CAFs) in the context of the tumor
microenvironment.
 To state the essential role of CAFs on tumor progression, invasion and
metastasis by acting as key suppliers of tumorigenic molecules, signaling
cancer cells in a paracrine fashion.
 To review current preclinical and clinical trials on anti-cancer
immunotherapy targeting CAFs or their crosstalk with cancer cells.
2. The tumor microenvironment
Cancer cells subsist in the tumor
microenvironment, i.e., a local
network of extracellular matrix
components and stromal cells, the
most abundant of which are CAFs1.
CAFs behave similarly to normal
activated fibroblasts, but, unlike
these, their active state seems to
be permanent. They interact with
tumor cells either through direct
contacts or paracrine signaling1,2.
Main components of the tumor stroma (adapted from2)
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4. Therapy: Neutralization of CAFs-secreted factors
1. Aims
3. CAFs – Cancer cells crosstalk
 Cancer progression is a dynamic process in which CAFs play an essential role.
 CAFs are the major source of tumorigenic factors not secreted (or at low rates) by cancer cells, including IGF-1,
HGF, VEGF, SDF-1, MMP-1 and MMP-9. They signal tumor cells towards progression, invasion and metastasis.
 Using immunotherapy to target the tumor stroma has recently emerged as a novel anti-cancer therapeutic
strategy. In this line, there are two approaches targeting the cross-talk between cancer cells and CAFs:
 Neutralization of CAFs-secreted tumorigenic factors, aiming to block the pathways they trigger.
 Enhancement of cytotoxic immune-responses towards CAFs in order to kill them.
6. Conclusions
5. Therapy: Cytotoxic responses against CAFs (FAP+ cells)
T-cells with a chimeric antigen receptor (CAR)
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CARs are expressed on T
cells. They combine the
specificity of antibodies
with the effector function
of T-cells4.
Structure of a CAR
Mice are transfected with FAP-CAR T-cells. The
domains VH and VL of the CAR recognize FAP+ cells
specifically and directly. Next, T cells are activated
and mediate cytotoxic responses towards FAP+ cells4.
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DNA vaccines against CAFs
contain pFAP (a plasmid
bearing the cDNA encoding
the entire murine FAP)5.
Upon vaccination, pFAP is released and enters murine
dendritic cells. There, its protein product (FAP) is
processed and presented by MHC-I, activating a TCD8+
cytotoxic response against FAP+ cells (mainly CAFs).
Dendritic cell vaccine (DC vaccine)
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In vivo
DCs derived from mice-extracted
monocytes are transduced with a
viral vector encoding FAP and/or
TRP-2. Readministration of these
DCs into mice triggers in vivo TCD8+-
cell mediated killing of FAP+ cells
(mainly CAFs) and/or TRP-2+ cells
(some cancer cells)6.
Constructs transducted into DCs in preclinical trials6
FAPCMV TRP-22a
Construct 3 had higher antitumor
activity than construct 2  New
therapies should focus on co-
targeting tumors and their stroma.
1
2
3
Normal
genome
Genome with
the vector 
integrated
pFAP
Dendritic cell
T CD8+ cells
Active
TCD8+ cells CAF (FAP
+)
Active
TCD8+ cell
Killed CAF 
(FAP+)
DNA vaccine – induced immune response
pFAPFAP
Subcutaneous
administration
Lower primary tumor growth
Increased survival
Decreased metastasis
Promising 
results from 
preclinical data5
CAFs communicate with cancer cells in a loop fashion and provide them
with tumorigenic molecules, including growth factors (HGF, IGF-1) and
cytokines (SDF-1). They also release factors acting on other cells (e.g.
VEGF binding endothelial cells) and matrix metalloproteinases (MMP-1,
MMP-9), essential for cancer cell invasion and metastasis1,2.
This strategy impairs the crosstalk between CAFs and cancer cells. By
neutralizing a CAF-secreted factor using an antibody, the pathway it activates
on cancer cells is blocked. It is a novel therapy, but already on clinical trials.
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